The company struggled to IPO but got public in late 2010 with a major valuation haircut (fraction of cash invested) as the only way to feed a very high burn rate supporting its formulation improvement for a generic migraine drug.
FORBES: Biotech's Capital Intensity Challenge: A Post-Mortem on 2007's Biggest Deals